JasonTYusteinMDPhD

Professor, Pediatric Hematology & Oncology Aflac Cancer and Blood Disorders Center Emory University

Dr. Yustein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

59 citations
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells.
Ilkka Liikanen, Colette R. Lauhan, Sara Quon, Kyla D. Omilusik, Anthony T. Phan
The Journal of Clinical Investigation. 2021-04-01
63 citations
Cross‐species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma
Wendy Allen-Rhoades, Lyazat Kurenbekova, Laura Satterfield, Neha Parikh, Daniel Fuja
Cancer Medicine. 2015-07-01
116 citations
High ALDH Activity Identifies Chemotherapy-Resistant Ewing's Sarcoma Stem Cells That Retain Sensitivity to EWS-FLI1 Inhibition
Ola Awad, Jason T. Yustein, Preeti Shah, Naheed Gul, Varalakshmi Katuri
Plos One. 2010-11-11

Journal Articles

Tegavivint and the Β-catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma
Nino Rainusso, Jason T Yustein, Journal of the National Cancer Institute

Rutledge Cancer Foundation’s Research Team Awarded a Two-Year NIH GrantMay 24th, 2021
The Faris Foundation Grant Funds Research for Advanced Sarcoma Clinical TrialDecember 4th, 2020